GREY MATTERS HEALTH INC (AGNPF)
AGNPF moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How AGNPF actually reacts to news — the realized, point-in-time move the market made, measured across 41 labeled events over the last three years with zero look-ahead.
AGNPF’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 14% | 28 |
| 30-min | 0.00% | 18% | 28 |
| 60-min | 0.00% | 25% | 28 |
| to close | 0.00% | 32% | 28 |
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when AGNPF moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AGNPF's baseline. Nothing else.
Recent AGNPF events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Grey Matters Announces the Closing of its Equity and Convertible Debenture Private Placement totalling CAD $1.12 Million | Press release | GlobeNewswire | +0.00% | -7.98% | |
| Grey Matters Achieves Final Major Milestone; Receives Radioactive Materials License from State of Florida for its Flagship NovaScan Neuroimaging Clinics™ Location | Press release | GlobeNewswire | -0.09% | -0.09% | |
| Grey Matters Retains Nationally Recognized ProScan to Read Brain Images from its Flagship NovaScan Neuroimaging Clinics™ Location in Florida | Press release | GlobeNewswire | — | — | |
| Grey Matters Appoints Radiologist Dr. Jayson A. Lord, MD as Medical Director of its First Dedicated PET Neuroimaging Clinic in the U.S. | Press release | GlobeNewswire | — | — | |
| Grey Matters Announces September Opening of its First Brain Dedicated PET Neuroimaging Clinic in the U.S. | Press release | GlobeNewswire | +0.00% | +25.88% | |
| Grey Matters Takes Delivery of the First Brain Dedicated PET Scanning System for its Flagship NovaScan Neuroimaging Clinic in Florida | Press release | GlobeNewswire | — | — | |
| Grey Matters Health Signs LOI with Catalyst MedTech for 200 Brain PET Scans for Alzheimer’s Clinical Trial at 2nd NovaScan Location Planned for Tampa | Press release | GlobeNewswire | — | — | |
| Algernon Health Announces Effective Date of Previously Announced Name Change to “Grey Matters Health Inc.” and its 10:1 Share Consolidation | Press release | GlobeNewswire | — | — | |
| Algernon Health Announces Proposed Name Change to “Grey Matters Health Inc.” and a 10:1 Share Consolidation | Press release | GlobeNewswire | -3.38% | -3.38% | |
| Algernon Health Announces NOVASCAN NEUROIMAGING CLINICS™ as the New Brand Name for its U.S. Brain PET Scanning Centers | Press release | GlobeNewswire | +0.00% | -11.84% | |
| Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building | Press release | GlobeNewswire | — | — | |
| Algernon Health Announces Private Placement | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Algernon Pharmaceuticals Completes Name Change to Algernon Health | Press release | GlobeNewswire | +0.00% | -9.97% | |
| Catalyst MedTech Launches "Connect" Program to Expand Access to Advanced Imaging; Announces Initial Partnership with Algernon Pharmaceuticals | Press release | PR Newswire | — | — | |
| Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer’s Detection | Press release | GlobeNewswire | +0.00% | +12.79% | |
| Algernon Announces Preferred Share Class Approved at Annual and Special Meeting | Press release | GlobeNewswire | +25.00% | +12.00% | |
| Algernon Pharmaceuticals Announces Name Change to Algernon Health | Press release | GlobeNewswire | +0.00% | +3.45% | |
| Algernon Announces Closing of the Private Placement Financing | Press release | GlobeNewswire | — | — | |
| Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000 | Press release | GlobeNewswire | — | — | |
| Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology | Press release | GlobeNewswire | +0.00% | -4.62% | |
| Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing | Press release | GlobeNewswire | — | — | |
| Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study | Press release | GlobeNewswire | +0.00% | -2.19% | |
| Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment | Press release | GlobeNewswire | +7.04% | +3.67% | |
| Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent | Press release | GlobeNewswire | +17.50% | +17.95% | |
| Algernon Pharmaceuticals Announces Closing of Private Placement | Press release | GlobeNewswire | — | — | |
| Algernon Pharmaceuticals Announces Increase to Private Placement | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services | Press release | GlobeNewswire | — | — | |
| Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024 | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024 | Press release | GlobeNewswire | +0.00% | -23.62% | |
| Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset | Press release | GlobeNewswire | +0.00% | -11.69% | |
| Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD | Press release | GlobeNewswire | +0.03% | +11.46% | |
| Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis | Press release | GlobeNewswire | — | — | |
| Algernon Pharmaceuticals Announces Closing of Private Placement | Press release | GlobeNewswire | -10.19% | +15.47% | |
| Algernon Pharmaceuticals Announces Increase to Private Placement | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Algernon Pharmaceuticals Announces Private Placement | Press release | GlobeNewswire | +0.00% | -5.95% | |
| Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position | Press release | GlobeNewswire | +0.00% | +24.67% | |
| Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast | Press release | GlobeNewswire | +0.00% | +0.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AGNPF section they belong to.
Where else AGNPF is measured.
AGNPF earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is GREY MATTERS HEALTH INC's median reaction calculated?
Every labeled AGNPF news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 41 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 18% of AGNPF's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AGNPF's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.